NOT-CA-12-002: Administrative Supplements for U.S. - China Biomedical Collaborative Research on Cancer, Mental Health, Allergy, Immunology, and Infectious Diseases including HIV/AIDS and its Co-morbidities

Administrative Supplements for U.S. - China Biomedical Collaborative Research on Cancer, Mental Health, Allergy, Immunology, and Infectious Diseases including HIV/AIDS and its Co-morbidities

Notice Number: NOT-CA-12-002

Key Dates
Release Date: December 2, 2011
Receipt Date: February 21, 2012
Earliest Anticipated Start Date: July 2, 2012

Issued by
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)

Purpose

This Notice announces an opportunity for eligible investigators receiving research funding from The National Institutes of Health (NIH) of the United States (U.S.) Department of Health and Human Services (HHS) to request administrative supplement support (additional funds to grants or cooperative agreements ). The “parent” awards and the proposed administrative supplements may be in various areas of cancer, mental health, or allergy, immunology and infectious diseases (including HIV/AIDS and its co-morbidities). The overall goal of this supplement program is to enhance ongoing research efforts through collaborations with Chinese scientists in these scientific areas under the new U.S.-China Program for Biomedical Research Cooperation.

This Administrative Supplement opportunity is available only to active research projects that are supported by specified NIH funding mechanisms. To be eligible, these awards must also be issued by the participating Institutes and Centers (I/C) (except for research related to HIV/AIDS and its co-morbidities). All the requests for supplemental funding must be based on collaborations involving eligible awardees and qualifying Chinese investigators. Additional specific requirements and eligibility conditions apply (see full details below).

Background
The NIH supports international collaborative biomedical research to advance science and expand biomedical knowledge. Scientific cooperation between the U.S. and the People’s Republic of China was initiated over 30 years ago and has grown rapidly in recent years. Recognizing that enhanced cooperative biomedical research would be of mutual benefit to the U.S. and China, the NIH Director and the President of the National Natural Science Foundation of China (NSFC) signed a Memorandum of Understanding (MOU) in October 2010.

NIH and NSFC further signed an Implementing Arrangement in December 2010 to develop a new U.S.-China Program for Biomedical Research Cooperation. A Joint Working Group (JWG), consisting of members from both NIH and NSFC, will develop strategic plans for collaboration and facilitate the expedited review and clearance of proposed bilateral projects. Both the NIH and NSFC have allocated funds to support joint activities pursued under this program.

The NIH and NSFC each plan to contribute funding for every collaborative project selected under the joint program (see details below).

General Requirements for Collaborative Arrangements
U.S. and Chinese collaborating investigators should work together to submit corresponding supplement requests in response to this Notice and NSFC applications to the corresponding NSFC announcement. The U.S. administrative supplement request to NIH and the linked Chinese application to NSFC must use the same title for the collaborative project (written in English).

Supplement requests from eligible U.S. investigators must be submitted in response to this Notice for administrative review and at NIH as outlined below. In the “Letter of Confirmation “ (see below), the U.S. applicant must expressly agree to provide directly a complete English copy of the request to their Chinese counterpart. The NIH will not consider for funding any request that has not met this sharing requirement. Potential U.S. applicants concerned about confidentiality or proprietary information should take this requirement into account before deciding what information to submit in their supplement request to NIH.

Eligibility for NSFC funding under these collaborative projects is limited to Chinese scientists who are current or former NSFC grantees. For eligible Chinese investigators, NSFC will publish a corresponding funding announcement (in Chinese) for Chinese investigators to apply for funding under the joint U.S.-China Program in Biomedical Research Cooperation (see http://www.nsfc.gov.cn/Portal0/InfoModule_396/More.htm). Applications from Chinese investigators will be reviewed in parallel by NSFC using selection factors that are harmonized with NIH selection factors. Chinese applicants will also be required to submit as part of their applications a copy of the NIH supplement request (that must be provided to them by their U.S. collaborator). Therefore, it is expected that the Chinese collaborator will contact the U.S. Project Director(s)/Principal Investigator(s) [PD(s)/PI(s)] and request copies of their supplement request in response to this announcement for submission of the Chinese application. This Chinese application will also be reviewed confidentially during the NSFC review process.

Funding decisions will be made by NIH and NSFC with consideration of the research priorities of both agencies. Both the U.S. and Chinese applications must be determined to be eligible and responsive (in the parallel processes conducted by the NIH and NSFC) to be considered for funding under the program.

Eligibility Requirements
Eligible “Parent” Grants or Cooperative Agreements. This supplement program is limited to current (active) grants or cooperative agreements using the following NIH funding mechanisms: R01, P01, U01, U19, U54, P30 (only for pilot projects to the Developmental Core with no additional funding to infrastructure), and P50. Moreover, to be eligible as a “parent” award, the grant or cooperative agreement must either be:

Funded by the NIH Institutes participating in this program [i.e., the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), or National Institute of Mental Health (NIMH)]; or
Focused on HIV/AIDS and its comorbidities (may be issued by any of the NIH Institutes/Centers) – funds for supplements will be allocated by the NIH Office of AIDS Research, OAR).

In addition:

Qualifying non-AIDS/HIV awards must be issued by NCI, NIAID, or NIMH (with award serial numbers containing either “CA”, “AI”, or “MH”); and
All “parent” awards must remain active through the entire period of the supplement (i.e., through July 2, 2013) (no-cost extensions cannot be used to accommodate this requirement).

NOT eligible as “parent” awards are grants or cooperative agreements that:

Use other NIH funding mechanisms than those listed above; or
Are NOT funded by either NCI, NIAID, or NIMH AND are NOT focused on HIV/AIDS and its comorbidities (including non-HIV/AIDS-related grants that are only co-funded by NCI, NIMH, and/or NIAID); or
Would expire or be in a "no-cost extension" status at any time before July 2, 2013.

NOTE: The U.S. PD(s)/PI (s)can only submit one administrative supplement request, even if the U.S. PD/PI has more than one active, eligible grant or cooperative agreement.

Research Objectives and Requirements for Supplement Requests
General Requirements

The parent grant/cooperative agreement must meet all the criteria stated above and the research proposed in the supplement must be accomplished within the competitive segment of the parent award.

The proposed supplement must be within the scope of the peer reviewed activities and aims approved within the parent grant.

IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project. The funding mechanism being used to support this program, i.e., administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives as long as they are within the original scope of the project. Any cost increases need to result from making modifications to the project in order to take advantage of opportunities that would increase the value of the project consistent with its originally approved objectives and purposes.

Supplement Scope and Specific Requirements

1. Supplemental funding under this program may be requested only to support research activities enhancing existing eligible "parent" grants or cooperative agreements through collaboration between U.S. and Chinese scientists.

A collaboration with an eligible NSFC Chinese investigator in China (submitting a corresponding Chinese application to NSFC) must be properly documented and formalized as instructed in this Notice. The Chinese collaborating investigator must also carefully follow all of NSFC’s application procedures to be considered eligible for review. Both U.S. and Chinese applications have to be considered eligible and responsive (by the NIH and NSFC, respectively). If these requirements are not met, administrative supplement requests will not be considered.

2. Funding under this program will support collaborative research projects only. Applications requesting funds for research infrastructure will not be considered.

3. Nature of Collaborative Research Activities. The intent of this initiative is to foster, stimulate, and/or expand collaborative basic, translational, and applied research between eligible NIH awardees and eligible Chinese researchers in the areas of cancer, mental health, allergy, immunology, and infectious diseases including HIV and its comorbidities.

As long as research activities proposed for the supplemental funding remain within the peer-reviewed scope of the NIH-supported eligible parent grant or cooperative agreement, this research may be basic, translational, behavioral, clinical, preventive, and/or epidemiological in nature.
Human subjects and/or animal research may be proposed for supplements but only if human subjects and/or animal research have been originally approved for the eligible parent grant or cooperative agreement.

4. Restrictions to Scientific Activities. The following activities are not allowed for these administrative supplements:

Human subject research or animal research if such activities have not been approved for the parent awards;
Clinical trials of drugs, biologics, or diagnostics (see NIH definition of clinical trials in the Application Guide SF424) For NIH definitions of clinical research vs. clinical trials, please see https://grants.nih.gov/grants/glossary.htm#C; and
Research involving Select Agents (see 42 CFR 73 for the Select Agent list; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant pathogens).

NOTE: Investigators considering application for these administrative supplements are strongly encouraged to contact the NIH Program Official assigned to the parent award for feedback about the eligibility of that award and whether the activities to be proposed meet the requirements defined for these administrative supplements.

Examples of Research Areas
Provided that supplements remain within the scope of eligible parent awards, supplemental projects may be focused on various areas relevant to cancer, mental health, or allergy, immunology and infectious diseases (including HIV/AIDS and its co-morbidities). Examples of research areas that are of interest to this collaborative program include (but are not limited to):

In cancer:

Studies of:

The pathobiology of cancers in China and/or the U.S.
Rare tumors for which the U.S.-China collaboration may help identify sufficient numbers of clinical cases for meaningful study
Infection-associated cancers
Cancer genomics, including epigenomic, transcriptomic, proteomic and metabolomic studies; systems biology and structural biology; Cancer nanotechnology; cancer cell and tumor biology; cancer stem cells; microenvironment and metastasis, tumor immunology and immunotherapy, and cancer etiology; inflammation and cancer
Cancer epidemiology and population science, including: investigations of infectious agents; nutrition; energy balance; environmental and occupational exposures or personal susceptibility factors that may affect cancer risk
Cancer prevention and screening, including: cost-effective screening; chemoprevention; nutrition and early detection
Preclinical development of novel cancer therapeutics and imaging agents
Traditional Chinese medicine to identify novel therapeutics in the pharmacopeia of traditional medical systems as defined by the World Health Organization (http://www.who.int/medicines/areas/traditional/definitions/en/index.html); or to use of complementary approaches to improve the therapeutic ratio of standard and investigational anti-cancer therapies; or research on lifestyle modifications (e.g., diet, exercise, mind-body approaches) and their effect on cancer outcomes (e.g., response to conventional cancer therapy, survival)

In mental health:

Analyses of the development, structure, and function of neural circuits with a focus on those most relevant to mental disorders. These studies could include anatomic and imaging projects in non-human primates.
Development of novel tools and methodologies, including imaging tools, assays that allow high throughput phenotyping within cell models, and improvements in stem cell techniques to study the molecular and cellular basis of mental disorders
Preclinical development of novel therapeutics for mental disorders
Identification of biomarkers with predictive value for diagnosis and treatment
Studies of the prodrome of schizophrenia

In allergy, immunology, and infectious diseases:

Asthma and allergic diseases, including the roles of environmental pollutants, infections, and allergens.
Basic immunology and immunity studies.
Research on infectious diseases (non-HIV/AIDS), in particular malaria, tuberculosis, dengue fever, enterovirus 71, rabies, schistosomiasis, measles, hepatitis, or influenza that address antimicrobial resistance (including mechanisms of resistance); resistance in disease vectors; and immune responses to infectious diseases or vaccines (including the role of immune responses in pathogenesis).

In HIV/AIDS:

HIV/AIDS and its co-morbidities including, but not limited to, co-infections, AIDS-defining and non-AIDS defining malignancies, and complications associated with long-term HIV disease and antiretroviral therapy, including tuberculosis, hepatitis C and hepatitis B, metabolic disorders, cardiovascular disease, conditions associated with aging, and neurologic and neurocognitive disorders.
Research toward a cure for HIV/AIDS including studies on: HIV reservoirs, latency, and persistence; screening and testing of novel compounds; developing and testing novel approaches combining virologic-, immunologic-, and cellular-based therapies, as well as strategies to activate latent virus; and adherence to treatment regimens, as well as research at the individual, community, and population levels on developing and implementing a cure for HIV/AIDS.

Funding Information
The number of administrative supplements awarded will be based on the merit of the requests received and the availability of funds. Up to $4,000,000 total costs (i.e., direct costs plus all applicable Facilities and Administration costs) will be available for this program from NIH in Fiscal Year 2012. Individual Administrative Supplements will be limited to $100,000 direct costs (or to 25 percent of the direct costs for the current budget year of the "parent" award, if that amount is lower than $100,000).

NSFC will provide complementary funds (approximately 300,000 Renminbi [Chinese currency] per project) for the Chinese co-investigators to engage in these projects. Five percent of the NSFC total award amounts can be used for indirect costs by Chinese institutions. The NIH and NSFC each plan to contribute funding for every project selected under the joint program.

Note 1: Whereas the U.S. parts of these collaborative projects will be funded as administrative supplements, the Chinese parts will be funded as new 1-year awards.

Note 2: In addition to the required standard budget for NIH funding (for expenses on the U.S. side), U.S. applicants are encouraged to include in their requests also a copy of the budget to be requested by their Chinese counterparts for NSFC funding (for expenses on the Chinese side in Chinese currency).

Preparation of Administrative Supplement Request
The administrative supplement request must describe the need for additional funding and categorical costs. Requests should be submitted on the PHS398 Application Guide forms (font size and other formatting rules apply as designated in the instructions) but following the instructions indicated below.

The requests must contain only the following elements:

1. Cover Letter, which cites this Notice (NOT-CA-12-002) and contains the following information:

NIH grantee Project Director/Principal Investigator (PD/PI) name and institution (Capitalize the family name; for example: Jane DOE);
Parent NIH grant number and title;
NIH Program Official named in the Notice of Award for the parent NIH award;
Title of the U.S.-China collaboration project;
Chinese Principal Investigator name (Capitalize the family name, and then provide the other given names; for example: DOE Jane);
Chinese Principal Investigator’s institution;
Amount of the requested supplement (for U.S. portion);
Names and titles of the U.S. Authorized Organizational Representative (AOR);
Phone numbers, e-mail addresses, and delivery addresses for the U.S. PD/PI and U.S. AOR; and
Signature of the U.S. AOR.

2. PHS 398 Form Page 1 (Face Page) MS Word PDF

The title of the project should be the title of the parent award.
This Notice (NOT-CA-12-002) should be cited in Box 2, and the yes box should be checked.
The PD/PI must be the same as the PD/PI on the parent award. For Multiple PDs/PIs on parent awards, the Contact PD/PI must be the PD/PI listed on the supplement request, and the supplement cannot change the Multiple PDs/PIs team.
The remaining items on the face page should be filled out in accordance with the PHS 398 application instructions.

3. PHS 398 Form Page 2 MS Word PDF

Note: The project summary is that of the administrative supplement, not the parent grant. The name of the U.S.-China collaboration project should be included at the beginning of the project summary section. An identical title (in English) must be included in the corresponding application to NSFC.

4. A brief description of the project that is being proposed in collaboration with the Chinese co-investigator, containing:

Introduction (limit 1 page) describing how the proposed supplemental activities relate to the parent award.
Specific Aims for the supplement (limit 1 page).
Research Strategy for the supplement (limit 6 pages):
Describe the proposed research explaining how it relates to the priority areas defined for this Administrative Supplement Program.
Explain also how the proposed supplemental activities will enhance research conducted under the parent award.
If the parent grant is a U01 cooperative agreement award, outline how the supplemental project will fit within the terms and conditions of the cooperative agreement award.
Include sufficient detail (e.g., on research design, methods, and data analysis) to allow assessment of the scientific merit of the proposed plans and the appropriateness of the request for supplemental funding in the context of the priorities of this Administrative Supplement Program.

5. Letter of Confirmation co-written and co-signed by the PD(s)/PI(s) of the parent NIH award and the Chinese co-investigator, and co-signed by the U.S. and Chinese AORs on the same page (limit 3 pages).

The first section of the letter of confirmation should: 1) indicate whether this is a new or existing collaboration; 2) describe specific responsibilities of the U.S. PD/PI and Chinese partner, detailing available resources, including which collaborative partner is contributing which resources, and a plan for how resources will be shared (e.g., individual contributions of specific reagents, patient samples, compounds, and access to populations for epidemiologic studies); and 3) include a written statement that the U.S. awardee organization will provide a copy of this application to the NSFC through their Chinese partner-collaborator.
The second part of the letter of confirmation should address the benefit of U.S.-China collaboration for the project, explaining why there is a need for international collaboration, what is the synergy between the collaborating groups, and how the project will achieve intellectual balance between the respective partners
The third part of the letter should include a discussion of future plans for expanding, extending, or otherwise continuing the joint research.

6. Biographical Sketches for all new key personnel who are additions on the supplemental project (two-page limit for each biographical sketch).

7. Itemized Budget for the Supplement (for the U.S. research expenses) with a justification that details the items requested, including personnel, travel, and Facilities and Administrative (F&A) costs.

Individual administrative supplement requests must not exceed $100,000 direct costs and are limited to 25 percent of the Institute Advisory Council-approved direct costs for the current budget year (the lower of these amounts is the maximum allowable). Awards will be for 1 year and the existing "parent" grant/cooperative agreement must have at least one (1) year of active funding remaining at the time that the supplement is awarded on July 2, 2012.

NOTE: The NIH requestors are encouraged to also include the budget for NSFC funding (for expenses on the Chinese side in Chinese currency [Renminbi]).

8. Human Subjects/Vertebrate Animal Documentation (if applicable).

Any differences in the involvement or use of human subjects or specimens, or use of vertebrate animals, between the administrative supplement activity and the parent grant should be noted and justified. For parent projects that were not initially approved for human or animal subjects research, an administrative supplement that proposes human or animal subjects research will be deemed out of scope.
The grantee institution must show evidence of compliance with U.S. and Chinese regulations for the conduct of research involving human subjects. Additional information can be found at the HHS Office for Human Research Protections website at http://www.hhs.gov/ohrp.
Include a current Human Subjects/Institutional Review Board (IRB) or Vertebrate Animals/Institutional Animal Care and Use Committee (IACUC) approval letter, if available. Otherwise, this will be required at the time of funding. All appropriate IRB and IACUC approvals must be in place prior to a supplement award being made. When appropriate, details should be provided on the protection of human subjects and inclusion of women, children, and minorities. Additional guidance on Human Subjects Research and Vertebrate Animals is provided under Part II of the PHS 398 instructions.
The Chinese collaborating site is also required to comply with human and animal assurances and certifications. If human subject or Vertebrate Animal research will be conducted in China, provide the Federalwide Assurance (FWA) number for the Chinese IRB and a brief (0.5-page) plan for obtaining IRB approval in China.

9. PHS 398 Checklist Form.

10. Import of Biospecimens (if applicable).
Include a written statement indicating whether or not biospecimens from China will be imported to the U.S.
If the proposed research requires exporting of biospecimens out of China, specify the type of biospecimens to be exported and provide evidence that you have already applied for the required Chinese government approval to export these materials (half-page limit). Also please specific whether or not the work can be completed if this approval is not granted. No funds will be awarded until you have approval to export samples outside of China or you indicate that the work can be performed within China.

Submitting an Administrative Supplement Request

NCI, NIAID and other NIH I/C awardees in the area of HIV/AIDS research are strongly encouraged to submit requests electronically as an attachment in pdf format via e-mail to the appropriate NIH I/C contact included below. These administrative supplement requests should include the parent grant number and identify this Notice (NOT-CA-12-002) in the e-mail subject field; the signature of the Authorized Organizational Representative (AOR) and the PD/PI must be clearly visible. The U.S. PD/PI (or a team of multiple PDs/PIs) can only submit one administrative supplement request, even if they have more than one active, eligible grant.
All NIMH administrative supplement requests should be submitted by the PD/PI of the parent grant electronically via the following link:

https://wwwapps.nimh.nih.gov/ssf/

When prompted, please log into the system with your eRA Commons ID and Password. Please select US-China Admin Supplements when prompted for the type of supplement.

As an alternative, administrative supplement requests can be submitted via CD to be mailed to the point of contact listed below (with the signature of the AOR clearly visible in the supplement request) and must be postmarked no later than February 21, 2012.

Administrative supplement requests may be submitted at any time, but must be received by no later than 5:00PM in the applicant’s local time zone on February 21, 2012.

Late submissions will not be considered.

All supplement requests must be submitted to the following contacts:

For administrative supplement requests for parent grants funded ny the NCI:

Bryan Baker
Office of Grants Administration
National Cancer Institute
6120 Executive Boulevard, EPS Suite T-44, MSC 7111
Bethesda, MD 20892-7111 (for U.S. Postal Service regular and express mail
Rockville, MD 20852 (for non-U.S. Postal Service delivery)
Telephone: (301) 496-9356
E-mail: [email protected]

For administrative supplement requests for parent grants funded by NIMH:

Rebecca Claycamp, MS, CRA
Chief, Grants Management Officer
National Institute of Mental Health
6001 Executive Blvd, Rm 6115
Bethesda, MD 20892-9605
Telephone: 301-443-2811
E-mail: r[email protected]

For administrative supplement requests for parent grants funded by NIAID:

Maggie C. Wells
Grants Management Specialist
National Institute of Allergy and Infectious Diseases
6700B Rockledge Drive, Room 2250, MSC 7614
Bethesda, MD 20892-7614
Telephone: (301) 594-9847
Fax: (301) 493-0597
E-mail: [email protected]

For administrative supplement requests for parent grants from other NIH Institutes and Centers in the area of HIV/AIDS and its co-morbidities:

Robert W. Eisinger, Ph.D.
Director of Scientific and Program Operations
and Chair, Therapeutics Coordinating Committee
Office of AIDS Research
National Institutes of Health
5635 Fishers Lane, Room 4015, MSC 9310
Bethesda, Maryland 20892-9310
Telephone: (301)-496-0358
Fax: (301)402-8638
E-mail: [email protected]

Selection
Administrative supplement requests will be evaluated administratively by NIH Staff. Selection factors will include the following:

Relevance of the proposed activities to the parent grant;
Adequate progress of the parent grant appropriate to the current stage of the project;
Appropriate and well-described plan to accomplish the goals within the timeframe proposed; and
Expertise of the research team proposed to conduct and achieve the goals the supplemental study.

Reviewers also will examine the appropriateness of the budgets in consideration of the study proposed and the research environment for the scientific projects.

Additional selection factors include:

Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator(s). Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If submitters are Early Stage Investigators or New Investigators, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? Do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Innovation. Does the proposed research challenge and seek to shift current understanding or clinical practice paradigms by utilizing novel theoretical concepts, approaches, or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach. Are the overall strategies, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
If the project involves research in human populations, are the plans for: 1) protection of human subjects from research risks; and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

Environment. Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Inquiries

Inquiries and discussion of plans for responding to this Notice are strongly encouraged. You may also refer to the Frequently Asked Questions (FAQ) page: http://www.niaid.nih.gov/TOPICS/GLOBALRESEARCH/EASTASIAPACIFIC/Pages/faq.aspx

For parents awards funded by the NCI:

Geraldina Dominguez, Ph.D.
Office of HIV and AIDS Malignancy
National Cancer Institute
Telephone: (301) 496-3204
E-mail: [email protected]

Julie A. Schneider, Ph.D.
Program Director, Center for Global Health
National Cancer Institute
Phone 301-496-6343
E-mail: [email protected]

For parents awards funded by the NIMH:

Phuong Kim Pham, Ph.D.
Office for Research on Disparities & Global Mental Health
National Institute of Mental Health
Telephone: 301-443-3724
E-mail: [email protected]

For parents awards funded by the NIAID:

Gayle Bernabe, M.P.H.
Regional Program Officer
Office of Global Research (OGR)
National Institute of Allergy and Infectious Diseases
Telephone: (301) 451-1018
E-mail: [email protected]

Ray Chen, M.D., M.S.P.H.
Medical Officer
Office of Global Research
National Institute of Allergy and Infectious Diseases

E-mail: [email protected]

Lara R. Miller, M.S.
Program Officer
Basic Immunology Branch
National Institute of Allergy and Infectious Diseases
Telephone: (301) 496-7551
E-mail: [email protected]

For parent awards funded by other NIH Institutes and Centers in the area of HIV/AIDS and its co-morbidities:

Robert W. Eisinger, Ph.D.
Director of Scientific and Program Operations
and Chair, Therapeutics Coordinating Committee
Office of AIDS Research
National Institutes of Health
Telephone: (301)-496-0358
E-mail: [email protected]